Si, Lu

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 175

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Tang, B., Yan, X., Sheng, X., Si, L., Cui, C., Kong, Y., Mao, L., Lian, B., Bai, X., Wang, X., et al. (2019) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 169

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 100

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

Wu, X., Yu, J., Yan, J., Dai, J., Si, L., Chi, Z., Sheng, X., Cui, C., Ma, M., Tang, H., et al. (2018) · Cancer Biology & Therapy

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 25

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 14